Table 4.
Comparison of current and revised criteria for prophylaxis against pneumocystis pneumonia in RA patients treated with b/ts-DMARDs
| Current criteria |
Model 1 |
Model 2 |
Model 3 |
|||||
|---|---|---|---|---|---|---|---|---|
| Age ≥65, lung disease, GC use |
Age, Alb, IgG |
Age, lung disease, BMI, Lymph, IgG |
Age |
|||||
| GC (−) | GC (+) | GC (−) | GC (+) | GC (−) | GC (+) | GC (−) | GC (+) | |
| Sensitivity | 0.625 | 0.444 | 1.000 | 0.667 | 1.000 | 0.778 | 0.875 | 0.556 |
| Specificity | 0.803 | 0.896 | 0.750 | 0.642 | 0.805 | 0.722 | 0.557 | 0.755 |
| AUC | 0.755 | 0.655 | 0.908 | 0.724 | 0.910 | 0.746 | 0.755 | 0.678 |
Power of prediction was calculated by the multivariable (Models 1, 2) or univariable (Model 3) logistic regression analysis and post-hoc ROC analysis. Independent variables entered in each model are shown in Table 2. AUC, area under the curve; GC, concomitant glucocorticoid use; Alb, serum albumin (g/dl); IgG, serum IgG (mg/dl); Lymph; lymphocyte count (/μl).